- Report
- April 2025
- 269 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2024
- 402 Pages
Global
From €4505EUR$4,950USD£3,827GBP
- Report
- July 2022
- 40 Pages
China
From €2913EUR$3,200USD£2,474GBP
- Report
- January 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
- Report
- January 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
- Report
- August 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,435GBP
- Report
- January 2024
- 250 Pages
Global
€4546EUR$4,995USD£3,861GBP
- Report
- September 2023
- 87 Pages
Middle East, Africa
From €2685EUR$2,950USD£2,281GBP
- Report
- September 2023
- 112 Pages
Europe
From €3140EUR$3,450USD£2,667GBP
- Report
- August 2023
- 73 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- November 2024
- 150 Pages
Europe
From €1438EUR$1,580USD£1,221GBP
€2054EUR$2,257USD£1,745GBP
- Book
- October 2012
- 1570 Pages
The Zoster Vaccine is a vaccine used to prevent shingles, a painful and debilitating condition caused by the varicella-zoster virus. It is recommended for adults over the age of 50, and is available in both single-dose and two-dose formulations. The vaccine is highly effective in preventing shingles, and can also reduce the severity of symptoms in those who do develop the condition. It is also recommended for those who have had chickenpox in the past, as they are at higher risk of developing shingles.
The Zoster Vaccine market is a subset of the larger Vaccines market, which includes a wide range of products used to prevent and treat infectious diseases. The Zoster Vaccine market is relatively small compared to other vaccine markets, but is growing as more people become aware of the risks associated with shingles.
Some companies in the Zoster Vaccine market include Merck, GlaxoSmithKline, Sanofi Pasteur, and Pfizer. Show Less Read more
